Search Clinical Trials in the EU

Duration

11-15 visits

Phase

Intake methods

Benefits

Drugs

Locations

Clinical Specialty

61-80 of 306 trials

Alzheimer's Disease: KarXT Medication Study

We are examining how well the medication KarXT is tolerated over a long period in people with psychosis related to Alzheimer's disease. This study aims to ensure the safety of this treatment for participants.

Psychosis Associated with Alzheimer's Disease1-2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementNeurologyPsychiatry

Long-Term Follow-Up for Gene-Modified T Cell Treatment

We are monitoring patients treated with gene-modified T cells to assess any delayed side effects and the long-term effectiveness of the treatment. This study also looks at the health of younger patients who received this therapy.

Malignant Lymphoid Neoplasm>2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visits Investigational Medicines Cost Reimbursement Partially RemoteHematologyInternal MedicineOncology

Multiple Myeloma: Elranatamab Treatment Study

We are studying the effectiveness of Elranatamab for patients with relapsed or refractory multiple myeloma who have already been treated with three different drug classes. This trial aims to see if it can help achieve better disease control.

Multiple Myeloma>2 yearsEfficacy phase (II)11-15 visits No Placebo Standard Medicines Partially RemoteHematologyOncology

Intra-Hepatic Cholangiocarcinoma: New Treatment Approaches

We are studying a combination of treatments for patients with inoperable intra-hepatic cholangiocarcinoma. The goal is to see if these treatments can improve survival and quality of life.

Non-resectable Cholangiocarcinoma>2 yearsMonitoring phase (IV)11-15 visits No Placebo Investigational MedicinesInternal MedicineOncology

Fibrotic Lung Disease: Inhaled Treprostinil Study

We are evaluating the long-term safety of inhaled treprostinil for individuals with fibrotic lung diseases. This study is for those who have previously participated in related trials and need ongoing treatment.

Lung Fibrosis>2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementInternal MedicinePulmonology

aHUS: Switching to Iptacopan Treatment

We are studying whether switching from anti-C5 antibody therapy to iptacopan can help people with aHUS avoid complications. The trial will also assess the safety and effects on blood and kidney health.

Atypical Hemolytic Uremic Syndrome6-12 monthsConfirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Standard Medicines Partially RemoteHematologyNephrology

Severe Brain Injury: Apomorphine Treatment Study

We are investigating whether apomorphine can help patients with disorders of consciousness. The study also aims to identify which patients may respond best to this treatment.

Severe Brain Injury and Disorder of Consciousness≤3 monthsEfficacy phase (II)11-15 visits No Placebo Standard Medicines Partially RemoteNeurology

Anti-NMDA Receptor Encephalitis: Inebilizumab Study

We are testing a new treatment called inebilizumab for people with anti-NMDA receptor encephalitis. The study aims to see if it helps improve disability compared to a placebo.

Anti-NMDA Receptor Encephalitis1-2 yearsEfficacy phase (II)11-15 visits Post-Trial Drug Access Investigational Medicines Partially RemoteInternal MedicineNeurology

Guselkumab for Pediatric Crohn’s Disease

We are studying the safety and effectiveness of guselkumab in children with moderately to severely active Crohn’s disease. This trial aims to see how well the treatment works after initial positive responses.

Crohn's Disease1-2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access Standard Medicines Cost Reimbursement Partially RemoteGastroenterologyPediatrics

Chronic Migraine: Dysport Treatment Study

We are studying whether Dysport can help reduce the number of migraine days in adults with chronic migraines. The trial will also look at its safety and overall effectiveness compared to a placebo.

Chronic Migraine1-2 yearsConfirmation phase (III)11-15 visits Standard Medicines Partially RemoteNeurology

Epcoritamab for Relapsed/Refractory Chronic Lymphocytic Leukemia

We are studying a new treatment called epcoritamab for patients with relapsed or refractory chronic lymphocytic leukemia and Richter's syndrome. The goal is to assess its safety and effectiveness, both alone and with other medications.

Chronic Lymphocytic Leukemia>2 yearsSafety phase (I)Efficacy phase (II)11-15 visits Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementOncology

Chronic Kidney Disease: Finerenone Safety Study

We are studying the long-term safety of finerenone for children and young adults with chronic kidney disease. This trial looks at its effects when used alongside standard treatments like ACE inhibitors or ARBs.

Chronic Kidney DiseaseProteinuria1-2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteNephrologyPediatrics

Hematologic Malignancies: MK-1026 Treatment Study

We are evaluating a new treatment for patients with blood cancers to see if it is safe and effective in reducing symptoms. This study focuses on various types of hematologic malignancies, including CLL and MCL.

Blood CancerEfficacy phase (II)11-15 visits No Placebo Investigational Medicines Cost Reimbursement Partially RemoteHematologyOncology

Triple-Negative Breast Cancer: MK-2870 with Pembrolizumab

We are studying a new treatment combining MK-2870 and pembrolizumab for people with triple-negative breast cancer who had surgery but did not respond completely. The trial aims to see if this combination works better than standard treatment options.

Triple Negative Breast Cancer>2 yearsConfirmation phase (III)11-15 visits No Placebo Investigational Medicines Cost ReimbursementOncology

Multiple Myeloma: HyQvia for Infection Prevention

We are studying whether HyQvia can help reduce infections in patients with newly diagnosed multiple myeloma who are not eligible for a transplant. The trial aims to see if it improves survival and quality of life compared to standard care.

Multiple Myeloma>2 yearsEfficacy phase (II)11-15 visits No Placebo Standard MedicinesHematologyInfectious Diseases

Lung Cancer: Avutometinib and Sotorasib Study

We are testing a combination of two medications for patients with KRAS G12C mutant non-small cell lung cancer. The goal is to find the best dose and see how well it works and how safe it is.

Non-small Cell Lung CancerSafety phase (I)Efficacy phase (II)11-15 visits Post-Trial Drug Access No Placebo Investigational MedicinesOncology

Childhood Onset Nephrotic Syndrome: Obinutuzumab vs. MMF

We are studying whether obinutuzumab is more effective and safer than MMF for children with childhood onset idiopathic nephrotic syndrome. We will also look at how these treatments affect fatigue and quality of life.

Childhood Idiopathic Nephrotic Syndrome1-2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementInternal MedicineNephrology

Efruxifermin for Non-Cirrhotic NASH/MASH

We are studying whether Efruxifermin can improve liver health and reduce fibrosis in people with Non-Cirrhotic NASH or MASH. Participants will be compared to those receiving a placebo to assess safety and effectiveness.

Non-alcoholic Fatty Liver DiseaseHepatic Fibrosis1-2 yearsConfirmation phase (III)11-15 visits Investigational MedicinesEndocrinologyHepatology

Combination Therapies for Advanced Esophageal Cancer

We are studying new treatment combinations for patients with advanced esophageal cancer who have already been treated with PD-1/PD-L1 therapies. The aim is to evaluate their safety and how well they work in shrinking tumors and improving survival.

Advanced Esophageal Squamous Cell Carcinoma>2 yearsSafety phase (I)Efficacy phase (II)11-15 visits Post-Trial Drug Access Investigational Medicines Partially RemoteOncology

Type 1 Diabetes: New Cell Therapy for Children

We are studying a new treatment combining cell therapy and an antibody for children with early-stage type 1 diabetes. The goal is to see if this approach can help delay the onset of diabetes symptoms.

Prediabetes>2 yearsEfficacy phase (II)11-15 visits Investigational MedicinesEndocrinologyInfectious DiseasesPediatrics

Search Clinical Trials in the European Union